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Thyroid eye disease (TED) is a complex inﬂammatory disease with a poorly understood etiopathogenesis.
It is often, but not always, associated with Graves’ disease and the endocrinologic manifestations of
hyperthyroidism. Controversy exists regarding optimal treatment of hyperthyroidism especially with
regard to the progression of orbitopathy. We review the literature examining the effectiveness of anti-
thyroid drugs, radioactive iodine, and thyroidectomy for long-term endocrinologic management, and
their effect on the progression of TED. In formulating an individualized treatment plan, considerations
include rates of recurrent hyperthyroidism, treatment-associated complications, and effect on TED
progression.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Thyroid eye disease (TED) is an autoimmune condition with a
reported incidence of 16/100,000womenand 2.9/100,000men, and
calculated prevalence of 0.25%. In a study of incident cases, nearly all
were associated with Graves’ disease (GD) compared with a small
fraction of patients with Hashimoto’s thyroiditis (3.3%). Endocrine
manifestations were heterogeneous, the majority of patients being
hyperthyroid (90%) compared with euthyroid (5.8%), and hypothy-
roid (0.8%).1 In the cohort of hyperthyroid patients, 20.3% of patients
were diagnosed with thyroid dysfunction at the time of TED diag-
nosis, 22.2% developed TED within 6 months of hyperthyroidism,
and 18.5% developed hyperthyroidism 6 months following TED
diagnosis. Thus, in the majority of patients there is a short latency
period between systemic and orbital disease diagnosis.1
Major risk factors for the development of TED inpatientswithGD
include female sex and smoking.Womenhavea 2.5-fold relative risk
of developing TED comparedwithmen,which is consistentwith the
female predominance in most autoimmune disorders.2 The preva-
lence of smoking among TED patients is greater than those with GD
and other thyroid diseases.3 Smokers have an 8-fold relative risk ofry or commercial interest in
logy, University of Michigan,
et, Ann Arbor, MI 48105, USA.
s).
ciety of Taiwan. Published by Elsedeveloping TED compared with nonsmokers.2 Active cigarette
smokers have an increased incidence of symptomatic TED, prop-
tosis, and diplopia comparedwith patientswho havenever smoked.
Former smokers experience the same risk as those patients who
never smoked, highlighting the importance of smoking cessation in
themanagement of TEDpatients.4 Smoking has also been associated
with increased severity of TED, although it is unclear if this risk is
dependent on the number of cigarettes consumed.3e5 Smoking
appears to confer an increased risk of TED progression in patients
undergoing radioactive iodine (RAI), and reduces the effectiveness
of steroid prophylaxis in these patients.6 In a recent study, active
smokers underwent an increased rate of strabismus surgery
compared with past smokers.7 Other associations including
ethnicity and TED development are less clear. Although a British
study suggested that European patients with GD are more likely to
develop TED than Asian patients, a subsequent study demonstrated
comparable incidence rates inpatients ofMalay, Chinese, and Indian
ethnicity with those of European patients.8,9
The close association between GD and onset of TED suggests a
common or overlapping pathogenesis. However, the relationship
between thyroid gland dysfunction and progression of TED is not
entirely understood. The thyroid stimulating hormone receptor
(TSHR) is a known autoantigen present on thyroid follicular cells,
adipocytes, and lymphocytes. Levels of TSHR antibodies (TSHR ab)
have been found to correlate to both TED severity and activity.10
Circulating bone marrow derived stem cells called ﬁbrocytes inﬁl-
trate the orbital and thyroid tissues and express TSHR and are
increased in abundance in TED patients compared with healthyvier Taiwan LLC. All rights reserved.
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pathogenesis.11
The effect of thyroid treatment on the pathogenesis of TED is
complex. Studies suggest that increased T3 levels are associated
with a higher probability of developing or worsening of pre-
existing TED, but these results have been inconsistent.12e14
Others have shown that regardless of treatment modality, the
development of hypothyroidism and increased TSH is associated
with the onset or progression of TED.13 Consequently, the over-
arching goal of thyroid treatment in TED patients is to achieve a
euthyroid state, as patients who are dysthyroid are more likely to
have severe TED.15 However, the ideal modality of hyperthyroid
treatment that safely achieves a euthyroid state with minimal to no
progression of TED is not well established. Most commonly used
treatment modalities include antithyroid drugs (ATDs), RAI, and
surgical thyroidectomy. Herein, we review the available data
regarding the effects these treatment modalities have on the
development and progression of TED.
2. Medical therapy
The mainstay of medical therapy in the management of hyper-
thyroid GD patients with TED is ATDs. The majority of ATDs belong
to the thionamide class and include propylthiouracil, methimazole,
and carbimazole. The latter is only available in Europe and Asia,
whereas the former two are generally used in the USA. Each
function to reduce the production of thyroid hormone by inhibiting
the coupling of iodothyronines.16 ATDs may be used for short-term
management in anticipation of RAI or surgical thyroidectomy, or for
long-term thyroid suppression. There are two major strategies
when using ATDs, the blockereplace regimen and the titration
regimen. In the former strategy, thyroid hormone production is
functionally “blocked” by taking a high dose of the ATD which will
completely suppress hormone production (dose will vary based on
the ATD used), and then “replaced” by levothyroxine at a dose that
results in a euthyroid state. This compares to the later strategy,
titration, where the dose of the ATD is lowered to the minimum
dose required to maintain a euthyroid state. A recent Cochrane
review of ATD regimens concluded that the titration regimen has
fewer adverse effects and is equally effective to the blockereplace
regimen for the management of hyperthyroidism; however none of
the 26 studies commented on the progression of TED.17
In the early 1990s, medical therapy utilizing ATDs were pre-
scribed as ﬁrst-line therapy by the majority of physicians in Europe
and Japan, and by approximately 30% of American Thyroid Associ-
ation members.18 Preferred practice methods shifted as the
numbers of ATD prescriptions in the USA increased from 1991 to
2008, indicating a trend towards medical treatment of hyperthy-
roidism.19 Common side effects that may occur with ATD use
include rash, fever, urticaria, and arthralgia in up to 5% of patients.16
Rare but major side effects of their use exist and may include
agranulocytosis, hepatotoxicity, aplastic anemia, and vasculitis.
Patients must be counseled regarding the signs and symptoms of
these potentially severe side effects, because in many cases onset
may be abrupt.
3. Radioactive iodine
RAI therapy utilizes the radioactive isotope 131I to inhibit thyroid
hormone production and causes progressive destruction of thyroid
follicular cells.16 It may be used as a ﬁrst-line treatment for hy-
perthyroidism or in cases of recalcitrant hyperthyroidism following
ATD treatment. Owing to the ability of the radioactive isotope to
cross the placental barrier and its excretion in breast milk, preg-
nancy and breastfeeding are contraindications to RAI therapy.20Reduction of hyperthyroidism may take several months, requiring
some patients to remain on ATD treatment following RAI until
euthyroidism is reached. In some cases of persistent hyperthy-
roidism, a second treatment of RAI may be required.
RAI was the ﬁrst-line therapy for GD in the USA in the early
1990s, and is now the preferred modality of treatment of uncom-
plicated GD for 45% of practitioners.18,21 It is effective in treating
hyperthyroidism and inducing hypothyroidism, with a reported
relapse rate of approximately 21e28%.22 Relapse rates as high as
48% have, however, been reported, and large goiter size is a risk
factor for recurrent hyperthyroidism.23 RAI is also able to effectively
normalize thyroid size in nearly all treated patients.24 However, RAI
treatment is associated with an initial increase in TSHR ab levels,
and by the end of a 5-year randomized study, patients treated with
RAI had signiﬁcantly higher TSHR ab levels at all stages after
treatment.12,25 Following RAI, patients should be closely monitored
for hypothyroidism and adequately replaced with levothyroxine if
present, as persistent hypothyroidism following RAI has been
shown to worsen TED, as discussed below.
4. Thyroidectomy
Surgical thyroidectomy involves total or subtotal removal of the
thyroid gland. It provides a rapid and effective method of treating
hyperthyroidism in GD. Thyroidectomy is the preferred method of
thyroid ablation in Europe and Asia, whereas RAI is preferred in the
USA.26 The rate of recurrent hyperthyroidism after subtotal thy-
roidectomy has been reported to be as high as 9%, which is signif-
icantly higher than after total thyroidectomy.26,27 Potential
complications of thyroidectomy include recurrent laryngeal nerve
paralysis and hypoparathyroidism, which may be temporary or
permanent. In a systematic review of both randomized and non-
randomized studies, a higher rate of both temporary and perma-
nent hypoparathyroidism was observed with total thyroidectomy
than with subtotal thyroidectomy, but there was no difference in
permanent recurrent laryngeal nerve palsy.28
5. Endocrine management and TED
A survey of members of The Endocrine Society, The American
Thyroid Society, and The American Association of Clinical Endocri-
nologists conducted in 2011 revealed that ATDs were the slightly
preferred modality for management in uncomplicated GD (53.9% of
responders, with RAI being preferred by 45% of practitioners, and
thyroidectomypreferred by0.7%).22 For patientswith TED, however,
ATDs were preferred by 62.9% of practitioners, thyroidectomy by
18.5%, RAIwith steroids by16.9%, andRAIwithout steroids by 1.9%.22
This change in preferred practice pattern reﬂects the underlying
concern of GD treatment on the onset or progression of TED.
It is generally accepted that medical therapy for Graves’ hyper-
thyroidism is not associated with progression of orbitopathy.29 Use
of ATDs causes a more rapid reduction in TSHR ab levels than sur-
gery or RAI, with up to 90% of patients achieving undetectable
levels of TSHR ab by 3 years after treatment.25 Because TSHR ab
levels have been shown to correlate with disease severity, there is a
theoretical beneﬁt to a more expedient decrease in circulating
TSHR ab levels.12 There does not appear to be a dose-dependent
effect, as a study comparing two different doses of methimazole
did not demonstrate a difference in the proportion of patients
whose orbitopathy improved or worsened during treatment.30
Several studies have compared the effect of RAI on TED to that of
ATDs. In one randomized trial comparing methimazole to RAI with
4 years of follow-up, 39% of patients treated with RAI experienced
worsening of new onset TED, compared with 21% of methimazole-
treated patients.31 In a subanalysis, however, RAI treatment was
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the rate of worsening of pre-existing TED did not signiﬁcantly differ
between the two treatment groups.31 Another randomized trial
comparing RAI to ATDs found that after 9 years of therapy, there
was no difference in the percentage of patients with worsened or
new onset TED, but that 37% of patients treated with RAI had an
improvement in TED compared with only 14% of those treated with
methimazole. Euthyroid status after treatment was correlated with
improved TED in both treatment groups.32 Similarly, a randomized
trial from Hong Kong showed that at 2 years following treatment,
the rates of developing new or worsened TED was similar in pa-
tients treated with RAI alone or a 12-month course of methimazole.
However, development of new or progression of TED was associ-
ated with hypothyroidism and increased TSH.13 Thus, most studies
show that RAI is associated with TED progression compared with
ATDs, which may be secondary to post-treatment hypothyroidism.
The use of prophylactic corticosteroids can prevent the wors-
ening of orbitopathy that is otherwise associated with RAI use.33e35
A cohort study of TED patients treated with RAI demonstrated
worsening orbitopathy, which was prevented in the few patients
who were treated with steroids.35 In other studies, RAI treatment
without corticosteroids was associated with progression of orbit-
opathy or new incidence of orbitopathy in 15% of patients, with the
majority of changes being observed within the ﬁrst 6 months after
treatment; this was in contrast to progressive or neworbitopathy in
3% of methimazole-treated patients and zero patients treated with
RAI and prednisone.14 Although there was no difference in pro-
gression or new incidence of TED in patients treated with RAI and
corticosteroids compared with those treated with methimazole,
67% of patients treated with RAI and corticosteroids had an
improvement in the severity of TED. This rate was signiﬁcantly
higher than the 2% of patients treated with methimazole demon-
strating improvement in TED.14 A systematic review of published
randomized controlled trials using RAI for hyperthyroidism showed
that RAI was associated with a relative risk of 4.2 for development
or progression of TED compared with ATDs, but not compared with
thyroidectomy; the relative risk of severe TED was 4.3-fold higher
in patients treated with RAI compared with ATDs.34 Prophylactic
steroids used with RAI were effective in reducing the risk of pro-
gression of TED to zero.34 In summary, the data demonstrate that
use of prophylactic glucocorticoids with RAI is effective in mini-
mizing the risk for progression of orbitopathy associated with RAI,
and may lead to improvement of TED. In addition, prevention of
early hypothyroidism may be beneﬁcial in preventing the pro-
gression of TED after RAI therapy. The ideal protocol for steroid
treatment is unknown.16 The European Group on Graves’ Orbitop-
athy (EUGOGO) recommends starting prednisone 0.3e0.5 mg/kg/
day orally 1e3 days after RAI and slowly tapering patients off over 3
months.36 A more recent retrospective study demonstrated that
use of only 0.2 mg/kg/day of prednisone, starting 1 day after RAI
and tapered off over 6 weeks was as effective as a higher doses of
0.3e0.5 mg/kg/day; more studies are needed to establish the best
glucocorticoid dosing regimen.37
One study compared the effects of methimazole, subtotal thy-
roidectomy, or RAI on progression of ophthalmopathy and found no
signiﬁcant difference in the rate of new or progressive ophthalm-
opathy in patients treated with methimazole (15%) compared with
surgery (11%), but a signiﬁcant increase in onset or progression of
TED was observed following RAI treatment.12 A systematic review
has shown that the relapse rate is signiﬁcantly higher with ATDs
(53%) compared with either RAI (15%) or thyroidectomy (10%); the
difference between RAI and thyroidectomy is not statistically sig-
niﬁcant.38 Three randomized controlled trials have compared the
effects of total thyroidectomy and subtotal thyroidectomy on pro-
gression of TED.27,39,40 These studies demonstrated that themajority of thyroidectomy patients had improvement in TED after
thyroidectomy (range, 50e89%) with no signiﬁcant difference be-
tween the different surgical groups.27,39,40 A meta-analysis of ran-
domized control trials comparing total thyroidectomy to subtotal
thyroidectomy also showed that there is no signiﬁcant difference in
TED progression between the two surgical approaches but recur-
rent hyperthyroidism was observed more frequently in patients
treated with subtotal thyroidectomy.26 A systematic review of both
randomized and nonrandomized studies conﬁrmed these ﬁnd-
ings.28 Thus, it has been consistently demonstrated that the choice
of subtotal or total thyroidectomy does not inﬂuence the progres-
sion of TED, and can indeed improve TED, in spite of differences in
rates of recurrent hyperthyroidism postoperatively. Similar to ATDs,
and in contrast to RAI, thyroidectomy also has the advantage of
lowering TSHR ab levels after treatment, with up to 90% of patients
achieving undetectable TSHR ab levels by postoperative year 4.256. Conclusions
There are many factors to consider when making recommen-
dations regarding treatment of hyperthyroidism in GD. Treatment
of hyperthyroidism with ATDs, RAI with corticosteroids, and thy-
roidectomy are not associated with worsening of TED, in contrast to
RAI alone. In general, any modality may be recommended for pa-
tients without TED, or with mild to moderate TED, whereas for
patients with severe TED thyroidectomy may be preferable due to
the rapid correction of hyperthyroidism and the lower risk of
progression of TED than that of RAI.167. Future directions
Immunotherapy is an additional strategy that is currently being
explored for the treatment of TED. In particular, the anti-CD-20
monoclonal antibody Rituximab, which inhibits B cell function,
has been explored in several clinical series.16 There are currently
three randomized clinical trials underway to explore the role of
Rituximab in the treatment of TED; however, speciﬁc recommen-
dations cannot be made until the results of these studies are
known.41 Furthermore, the effects of Rituximab as an adjuvant
therapy in patients being treated for hyperthyroidismwill also need
to be studied in large randomized clinical trials. Until such data are
available, it is not possible to make recommendations comparing
use of Rituximab with ATDs, RAI, or thyroidectomy. Additional
immunotherapies are also under development, which may be
promising; however, at this time there is insufﬁcient data to make
formal recommendations.Acknowledgments
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